Digestery
Longevity supplements › Metformin and Aging › Studies

Opinion or narrative review

Review of metformin use beyond diabetes, including aging, with trials planned

Triggle and colleagues · Metabolism: clinical and experimental · 2022

Original title: Metformin: Is it a drug for all reasons and diseases?

Under review. A person has not yet checked this summary against the paper. It is written from the PubMed abstract. Until a person checks it, search engines are asked not to list this page.

What the study found

No direction

The authors conclude metformin's main benefits come from lowering blood sugar and improving insulin response, which lowers risk of some diseases and may add to healthy years of life. Some benefits, like better blood vessel function, may not depend on blood sugar.

The study at a glance

Type of study
Opinion or narrative review
Who or what was studied
People and lab models studied for metformin use beyond diabetes, including aging
What was tested
Review of what metformin does and whether it helps in many diseases, including aging (MILES and TAME trials are planned)
Who has a stake
No disclosure in PubMed
No disclosure in PubMed.
Journal
Metabolism: clinical and experimental, 2022
Source
PubMed record 35640743. This page is based on the abstract only.

How much this study counts

  • –An opinion or narrative review: no new data, and no set method for choosing which studies to discuss.
  • •The PubMed record has no conflict-of-interest statement.
  • •Summarized from the PubMed abstract only. The full paper may hold details the abstract leaves out.

✓ Strength– Limit• Note

These points come from fixed rules about the type of study, its size and length, what it measured, and who has a stake. Every study on Digestery gets the same rules.

Where this study sits

This paper is not on the ladder. It is a opinion or narrative review, and reviews and opinion pieces discuss studies that are already counted on the steps below.

↑ Stronger evidence

  1. Trials in people: aging and age-related disease

    1

    1 benefit

  2. Trials in people: other measures

    3

    2 no difference, 1 harm

  3. Trials in people: lab tests or safety

    6

    2 benefit, 2 mixed, 2 no difference

  4. Population studies

    8

    6 benefit, 2 no difference

  5. Blood levels and genes

    0

    None among the papers we read.

  6. Animals

    3

    2 benefit, 1 harm

↓ Weaker evidence

  • Points to benefit
  • Mixed
  • No difference
  • No direction
  • Points to harm

How it fits with the other research

The short answer to “Does metformin slow aging in people without diabetes?”

Not shown in people without diabetes.

Confidence: low. Based on 26 on-topic papers.

Read the full answer
  • On the watch list: Large aging trials in people without diabetes.

Other opinion on this question

See all 26 studies on this question

How this page was made

Label

First read of the abstract
Claude Sonnet
Independent second read
Claude Haiku
Differences settled
The two reads differed. The reviewer checked the abstract and kept the first read. Claude Opus 5.5.
Headline
Claude Sonnet, from the checked study record. A script checked its numbers and wording.
Numbers
Checked against the abstract by a script
“How much this study counts”
Fixed rules, the same for every study
Source check by a person
Not yet. Required before search engines may list this page.

Spot an error? Email a flag with a link to your source, or use the form on the question page.